Natural NO or Drug Product	Patient population	Route of administration	NO concentration (ppm)	Exposure duration/ day	NO exposure/ day (AUC, ppm*hr)	Treatment duration
FeNO*	Adults	Exhaled air	0.02-0.1**	8 hours	0.16-0.8	Naturally occurring
INOmax	Neonates	Inhalation	5-20	Up to 24 hours	120-480	Up to 4 days (Canada) Up to 14 days (US)
NONS prevention	Adults	Nasal spray	≤1.5	Up to 25 min	0.2	28 days
NONS treatment	Adults	Nasal spray	≤1.5	Up to 25 min	0.6	7 days
Safety Margin of NONS vs. INOmax			**3.3-13 fold**	**57-fold**	**>600-fold (prevention)** **>200-fold (treatment)**	**Identical (US)** **Longer (Canada)**

** FeNO – fraction exhaled concentration; **NO concentration in exhaled air determined under variety of physiological conditions*

FIG. 1




FIG. 2a



log CFU/ml
0
1
2
3
4
5
6
7
8
9
Anaerobe (Fusobacterium sp)
Gram + ve (S. aureus)
Gram -ve (P. aeruginosa)
Control
NORG
NORS+NORG

FIG. 2b



FIG. 3a



FIG. 3b



FIG. 3c




FIG. 3d

Day 14




FIG. 3e




FIG. 3f



FIG. 4a





FIG. 4b



Pre Treatment

FIG. 4c




1 overnight Tx

FIG. 4d




3 weeks Tx (overnight)

FIG. 4e




2 months Post Tx

FIG. 4f



4 months Post Tx

FIG. 4g



9 months Post Tx

FIG. 4h

Day 1

Index Toe



Fourth Toe





FIG. 4i

Day 28

Index Toe



Fourth Toe





FIG. 4j

Day 63

Index Toe




Fourth Toe



FIG. 4k

Day 77

Index Toe



Fourth Toe





FIG. 4I

Day 120

Index Toe



* Tip of medium toe is bruised from running. Scab showing. 3 weeks old

Fourth Toe




FIG. 4m